FHA
HRTX icon

Flagship Harbor Advisors’s Heron Therapeutics HRTX Stock Holding History

Flagship Harbor Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$3K – 2095
2018
Q2 		$3K Buy
+100
New +$3.18K ﹤0.01% 1770

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Flagship Harbor Advisors's HRTX Position: Q3 2018 in Review

Flagship Harbor Advisors sold out of Heron Therapeutics (HRTX) in Q3 2018, closing a stake of 100 shares — an estimated $3K sold.

Flagship Harbor Advisors first reported a position in HRTX in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 194 funds tracked by Wall St. Rank hold HRTX as of Q3 2018.

  • Flagship Harbor Advisors reported no remaining Heron Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Flagship Harbor Advisors sold 100 Heron Therapeutics shares in Q3 2018, an estimated $3K.
  • Flagship Harbor Advisors first reported a position in Heron Therapeutics in Q2 2018 and held it in 1 quarter.
  • Flagship Harbor Advisors's Heron Therapeutics position peaked at $3K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2018.

Based on Flagship Harbor Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.